Recruitment too low

This is a multicenter prospective study:2 independant cohorts of patients with OMS grade II glioma will be followed during 5 years.

• cohort A: patients in first-line treatment (surgery, radiotherapy or chemotherapy)
• cohort B: patients with disease simple monitoring.

The primary endpoint is to evaluate the impact of tumor and treatments on neurocognitive functions and quality of life, using validate and standard tests.

Inclusion Criteria:

• OMS grade II glioma
• signed informed consent
• age >=18
• IK >=80%
• ability to read, write and undertand French

Exclusion Criteria:

• glioma localized to brainstem
• other neurologic or psychiatric disease
• history of other malignancies, other than curatively treated in-situ carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization
• neuroleptic concomitant treatment
• pregnant or lactating women